AI Insight
Researchers have discovered that traditional clinical criteria for identifying multiple myeloma patients with poor prognosis may need revision in light of newer treatment approaches. The study, published in the peer-reviewed journal Cancer, suggests that the indicators used to predict which blood cancer patients have low survival chances should be updated to reflect how modern therapies have changed disease progression and outcomes.
Why it matters
Updating prognostic criteria could help clinicians make more accurate treatment decisions and better identify which multiple myeloma patients require more aggressive or alternative therapeutic interventions. This may improve patient outcomes by ensuring appropriate treatment intensity is matched to actual risk levels under current treatment paradigms.
Understand the Science
Researchers have found that, with new treatments for multiple myeloma, a serious type of blood cancer, clinicians should use different criteria to identify patients with poor chances of survival. The study was published online in Cancer.
Source: Have the clinical signs of a serious type of blood cancer changed?